Cargando…

Characterization of erythroferrone oligomerization and its impact on BMP antagonism

Hepcidin, a peptide hormone that negatively regulates iron metabolism, is expressed by bone morphogenetic protein (BMP) signaling. Erythroferrone (ERFE) is an extracellular protein that binds and inhibits BMP ligands, thus positively regulating iron import by indirectly suppressing hepcidin. This al...

Descripción completa

Detalles Bibliográficos
Autores principales: Mast, Jacob F, Leach, Edmund A E, Thompson, Thomas B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10491252/
https://www.ncbi.nlm.nih.gov/pubmed/37693455
http://dx.doi.org/10.1101/2023.09.01.555965
_version_ 1785104022211919872
author Mast, Jacob F
Leach, Edmund A E
Thompson, Thomas B
author_facet Mast, Jacob F
Leach, Edmund A E
Thompson, Thomas B
author_sort Mast, Jacob F
collection PubMed
description Hepcidin, a peptide hormone that negatively regulates iron metabolism, is expressed by bone morphogenetic protein (BMP) signaling. Erythroferrone (ERFE) is an extracellular protein that binds and inhibits BMP ligands, thus positively regulating iron import by indirectly suppressing hepcidin. This allows for rapid erythrocyte regeneration after blood loss. ERFE belongs to the C1Q/TNF related protein (CTRP) family and is suggested to adopt multiple oligomeric forms: a trimer, a hexamer, and a high molecular weight species. The molecular basis for how ERFE binds BMP ligands and how the different oligomeric states impact BMP inhibition are poorly understood. In this study, we demonstrated that ERFE activity is dependent on the presence of stable dimeric or trimeric ERFE, and that larger species are dispensable for BMP inhibition. Additionally, we used an in-silico approach to identify a helix, termed the ligand binding domain (LBD), that was predicted to bind BMPs and occlude the type I receptor pocket. We provide evidence that the LBD is crucial for activity through luciferase assays and surface plasmon resonance (SPR) analysis. Our findings provide new insight into how ERFE oligomerization impacts BMP inhibition, while identifying critical molecular features of ERFE essential for binding BMP ligands.
format Online
Article
Text
id pubmed-10491252
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cold Spring Harbor Laboratory
record_format MEDLINE/PubMed
spelling pubmed-104912522023-09-09 Characterization of erythroferrone oligomerization and its impact on BMP antagonism Mast, Jacob F Leach, Edmund A E Thompson, Thomas B bioRxiv Article Hepcidin, a peptide hormone that negatively regulates iron metabolism, is expressed by bone morphogenetic protein (BMP) signaling. Erythroferrone (ERFE) is an extracellular protein that binds and inhibits BMP ligands, thus positively regulating iron import by indirectly suppressing hepcidin. This allows for rapid erythrocyte regeneration after blood loss. ERFE belongs to the C1Q/TNF related protein (CTRP) family and is suggested to adopt multiple oligomeric forms: a trimer, a hexamer, and a high molecular weight species. The molecular basis for how ERFE binds BMP ligands and how the different oligomeric states impact BMP inhibition are poorly understood. In this study, we demonstrated that ERFE activity is dependent on the presence of stable dimeric or trimeric ERFE, and that larger species are dispensable for BMP inhibition. Additionally, we used an in-silico approach to identify a helix, termed the ligand binding domain (LBD), that was predicted to bind BMPs and occlude the type I receptor pocket. We provide evidence that the LBD is crucial for activity through luciferase assays and surface plasmon resonance (SPR) analysis. Our findings provide new insight into how ERFE oligomerization impacts BMP inhibition, while identifying critical molecular features of ERFE essential for binding BMP ligands. Cold Spring Harbor Laboratory 2023-09-02 /pmc/articles/PMC10491252/ /pubmed/37693455 http://dx.doi.org/10.1101/2023.09.01.555965 Text en https://creativecommons.org/licenses/by-nc-nd/4.0/This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which allows reusers to copy and distribute the material in any medium or format in unadapted form only, for noncommercial purposes only, and only so long as attribution is given to the creator.
spellingShingle Article
Mast, Jacob F
Leach, Edmund A E
Thompson, Thomas B
Characterization of erythroferrone oligomerization and its impact on BMP antagonism
title Characterization of erythroferrone oligomerization and its impact on BMP antagonism
title_full Characterization of erythroferrone oligomerization and its impact on BMP antagonism
title_fullStr Characterization of erythroferrone oligomerization and its impact on BMP antagonism
title_full_unstemmed Characterization of erythroferrone oligomerization and its impact on BMP antagonism
title_short Characterization of erythroferrone oligomerization and its impact on BMP antagonism
title_sort characterization of erythroferrone oligomerization and its impact on bmp antagonism
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10491252/
https://www.ncbi.nlm.nih.gov/pubmed/37693455
http://dx.doi.org/10.1101/2023.09.01.555965
work_keys_str_mv AT mastjacobf characterizationoferythroferroneoligomerizationanditsimpactonbmpantagonism
AT leachedmundae characterizationoferythroferroneoligomerizationanditsimpactonbmpantagonism
AT thompsonthomasb characterizationoferythroferroneoligomerizationanditsimpactonbmpantagonism